Ahren Innovation Capital has led a $16m initial series A tranche for Mogrify, co-founded by researchers from Bristol, Monash and Duke universities.
Mogrify, a UK-based cell conversion technology developer with links to Bristol, Monash and Duke universities, today raised a $16m first series A tranche led by patient capital fund Ahren Innovation Capital.
Parkwalk Advisors, the fund management subsidiary of commercialisation firm IP Group, contributed to the round both directly and through its University of Bristol Enterprise Fund III. Private equity firm 24Haymarket also took part.
Incorporated in 2016, Mogrify is working on direct cellular conversion technology that enables any…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
